OCUL Ocular Therapeutix, Inc.

9.17
-1  -7%
Previous Close 9.61
Open 9.84
Price To book 4.62
Market Cap 263.69M
Shares 28,756,000
Volume 1,402,535
Short Ratio 4.20
Av. Daily Volume 1,085,790

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released November 14, 2016. Primary endpoints met.
DEXTENZA
Post-surgical ocular inflammation and pain
Phase 3 trial did not meet primary endpoint - June 2016
DEXTENZA
Allergic conjunctivitis
Phase 3 initiated October 2016. Data due 1H 2018.
OTX-TP
Glaucoma and ocular hypertension
CRL July 25 2016 - due to manufacturing deficiencies. NDA resubmitted, PDUFA date July 19, 2017.
DEXTENZA
Ocular inflammation and pain following cataract surgery
Phase 2 complete. Assessing plans forward.
DEXTENZA
Dry Eye Disease

Latest News

  1. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Change in Directors or Principal Officers
  2. Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: Q4, 2016 By the Numbers : March 20, 2017
  3. Positive Results Reported For Ocular Therapeutix Inc (OCUL) Dextenza Following Phase III Study
  4. Why Ocular Therapeutix Inc Saw its Share Price Jump Today
  5. OCULAR THERAPEUTIX, INC Financials
  6. Ocular's Dextenza Reports Positive Study Results
  7. After setback, Bedford eye care biotech has its sights set on FDA approval
  8. New Publication Describes Positive Patient Experience in Study of Ocular Therapeutix’ DEXTENZA™ Following Cataract Surgery
  9. Ocular Therapeutix, Inc. :OCUL-US: Earnings Analysis: 2016 By the Numbers : March 14, 2017
  10. Edited Transcript of OCUL earnings conference call or presentation 10-Mar-17 1:30pm GMT
  11. Ocular Therapeutix Inc Earnings Call scheduled for 8:30 am ET today
  12. Ocular Therapeutix reports 4Q loss
  13. Ocular Therapeutix reports 4Q loss
  14. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and E
  15. Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2016 Financial Results
  16. Q4 2016 Ocular Therapeutix Inc Earnings Release - Before Market Open
  17. Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2016 Financial Results
  18. Biotech Movers And Shakers: Ocular Therapeutix Inc (OCUL) And Argos Therapeutics Inc (ARGS)
  19. Blog Coverage Ocular Therapeutix Announced FDA Acceptance of NDA Resubmission for its Product for the Treatment of Ocular Pain
  20. OCULAR THERAPEUTIX, INC Files SEC form 8-K, Other Events